Support provided by an independent educational grant from Allergan, Astellas and Medtronic

CME Available: https://auau.auanet.org/node/24584

Instructional Course Director(s)

Eric Rovner, MD

Medical University of South Carolina

Instructional Course Faculty(s)

Alan Wein, MD,PHD

Founders Professor and Emeritus Chief of Urology and Director, Residency Program

University of Pennsylvania

Christopher Chapple, MD

Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Sheffield Hallam University

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled "Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults, the proceedings of the 5th International Consultation on Incontinence," as well as European Association of Urology (EAU) Guidelines, has rekindled interest in this area. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy. Currently available agents as well as drugs in development will be discussed.

Learning Objectives:

Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB)

Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.

Realize the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies

Analyze the clinical (and theoretical) advantages and limitations of currently available agents

Review potential future pharmacological pathways and therapies for OAB